Dihydromuscimol
Left: (S)-dihydromuscimol Right: (R)-dihydromuscimol | |||
| Clinical data | |||
|---|---|---|---|
| Other names | DHM; 4,5-Dihydromuscimol | ||
| Drug class | GABAA receptor agonist; GABA reuptake inhibitor | ||
| ATC code |
| ||
| Identifiers | |||
| |||
| CAS Number | |||
| PubChem CID | |||
| ChemSpider | |||
| ChEMBL | |||
| CompTox Dashboard (EPA) | |||
| Chemical and physical data | |||
| Formula | C4H8N2O2 | ||
| Molar mass | 116.120 g·mol−1 | ||
| 3D model (JSmol) | |||
| |||
| |||
Dihydromuscimol (DHM), or 4,5-dihydromuscimol, is a synthetic GABAA receptor agonist and GABA reuptake inhibitor which was derived from the Amanita muscaria constituent muscimol.[1][2][3] The compound is a dihydroisoxazole derivative.[4]
The compound has two enantiomeric forms. (S)-Dihydromuscimol is a selective and extremely potent GABAA receptor agonist, while (R)-dihydromuscimol is a GABA reuptake inhibitor and a weak GABAA receptor agonist.[5][6][7][8] Dihydromuscimol is equipotent to muscimol as a GABAA receptor agonist but is more potent as a GABA reuptake inhibitor.[7][8] However, (S)-dihydromuscimol is slightly more potent than muscimol as a GABAA receptor agonist.[6] The enantiomer is the most potent GABAA receptor agonist that has been discovered as of 2004.[1][8]
Dihydromuscimol was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1979.[4][3] The aminomethyl side chain of dihydromuscimol may be just as susceptible to metabolism as that of muscimol, and hence the drug has not been extensively used in animal studies.[9]
See also
[edit]- Thiomuscimol
- Gaboxadol (THIP)
- 4-AHP
- 4-PIOL
References
[edit]- ^ a b Krogsgaard-Larsen P, Frølund B, Liljefors T, Ebert B (October 2004). "GABAA agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic". Biochem Pharmacol. 68 (8): 1573–1580. doi:10.1016/j.bcp.2004.06.040. PMID 15451401.
Muscimol, a constituent of the mushroom Amanita muscaria, has been extensively used as a lead for the design of different classes of GABA analogues (Fig. 2). The 3-isoxazolol carboxyl group bioisostere of muscimol can be replaced by a 3-isothiazolol or 3-hydroxyisoxazoline group to give thiomuscimol and dihydromuscimol, respectively, without significant loss of GABAA receptor agonism [36]. (S)-Dihydromuscimol is the most potent GABAA agonist so far described [37]. The structurally related muscimol analogues, isomuscimol and azamuscimol, on the other hand are virtually inactive, emphasizing the very strict structural constraints imposed on agonist molecules by the GABAA receptors [36].
- ^ Rahbaek L, Christophersen C (2001). "The isoxazole alkaloids". Alkaloids Chem Biol. The Alkaloids: Chemistry and Biology. 57: 185–233. doi:10.1016/s0099-9598(01)57004-2. ISBN 978-0-12-469557-3. PMID 11705121.
The analog dihydromuscimol or 5-aminomethylisoxazolin-3-ol has been one of the derivatives extensively investigated for its physiological properties. It has not so far been found in nature (75).
- ^ a b Krogsgaard-Larsen P, Hjeds H, Curtis DR, Lodge D, Johnston GA (June 1979). "Dihydromuscimol, thiomuscimol and related heterocyclic compounds as GABA analogues". J Neurochem. 32 (6): 1717–1724. doi:10.1111/j.1471-4159.1979.tb02284.x. PMID 448364.
- ^ a b Rivera-Illanes D, Recabarren-Gajardo G (September 2024). "Classics in Chemical Neuroscience: Muscimol". ACS Chem Neurosci. 15 (18): 3257–3269. doi:10.1021/acschemneuro.4c00304. PMID 39254100.
- ^ Krogsgaard-Larsen P, Frølund B, Kristiansen U, Frydenvang K, Ebert B (1997). "GABAA and GABAB receptor agonists, partial agonists, antagonists and modulators: design and therapeutic prospects". European Journal of Pharmaceutical Sciences. 5 (6): 355–384. doi:10.1016/S0928-0987(97)10009-4.
Dihydromuscimol is a more rigid analogue of GABA, and whilst (S)-dihydromuscimol is a selective and extremely potent GABA A agonist, (R)-dihydromuscimol is a weak GABAA agonist and an inhibitor of GABA uptake (Krogsgaard-Larsen et al., 1986).
- ^ a b Petersen JG, Bergmann R, Krogsgaard-Larsen P, Balle T, Frølund B (June 2014). "Probing the orthosteric binding site of GABAA receptors with heterocyclic GABA carboxylic acid bioisosteres". Neurochem Res. 39 (6): 1005–1015. doi:10.1007/s11064-013-1226-6. PMID 24362592.
Muscimol, which has been widely used in the study of GABAAR, and the analogues (RS)-dihydromuscimol and thiomuscimol all display potencies for the GABAAR in the low nanomolar range (Table 1). The two enantiomers of dihydromuscimol display different pharmacological properties. The (S)-enantiomer shows high affinity for the GABAAR, whereas the inhibition of GABA uptake via GABA transporters displayed by dihydromuscimol proved to reside exclusively in the R-enantiomer [32]. [...] Relative agonist potencies at the GABAAR of the heterocylic muscimol analogues are (S)-dihydromuscimol > muscimol > thiomuscimol > 4-AHP >> azamuscimol as shown in Table 1.
- ^ a b Høg S, Greenwood JR, Madsen KB, Larsson OM, Frølund B, Schousboe A, et al. (2006). "Structure-activity relationships of selective GABA uptake inhibitors". Curr Top Med Chem. 6 (17): 1861–1882. doi:10.2174/156802606778249801. PMID 17017962.
4,5-Dihydromuscimol is equipotent with muscimol at the GABAA receptor, and it is more potent as an inhibitor of neuronal than glial GABA uptake systems [39]. The enantiomers of dihydromuscimol showed different pharmacology. The uptake activity resides with the (R)-enantiomer, unlike the GABAA receptor binding affinity conferred by the (S)- enantiomer. (R)-Dihydromuscimol displays a weak preference for neuronal uptake systems [27].
- ^ a b c Krogsgaard-Larsen P, Nielsen L, Falch E, Curtis DR (November 1985). "GABA agonists. Resolution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol". J Med Chem. 28 (11): 1612–1617. doi:10.1021/jm00149a012. PMID 2999396.
- ^ Krogsgaard-Larsen P, Falch E (August 1981). "GABA agonists. Development and interactions with the GABA receptor complex". Mol Cell Biochem. 38 Spec No (Pt 1): 129–146. doi:10.1007/BF00235692. PMID 6270544.